Analysts’ Weekly Ratings Changes for Prothena (PRTA)

Several brokerages have updated their recommendations and price targets on shares of Prothena (NASDAQ: PRTA) in the last few weeks:

• 7/28/2026 – Prothena was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/25/2026 – Prothena was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/24/2026 – Prothena had its “buy” rating reaffirmed by UBS Group AG.
• 7/24/2026 – Prothena had its “buy” rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.
• 7/9/2026 – Prothena was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/23/2026 – Prothena was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Activity

In related news, insider Anne Evans Kingston sold 7,662 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $8.47, for a total value of $64,897.14. Following the completion of the sale, the insider owned 55,782 shares of the company’s stock, valued at approximately $472,473.54. This represents a 12.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel Michael John Isaacs sold 8,386 shares of Prothena stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $8.47, for a total transaction of $71,029.42. Following the transaction, the general counsel directly owned 35,745 shares in the company, valued at $302,760.15. This trade represents a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have bought 345,000 shares of company stock valued at $3,097,250. 10.40% of the stock is currently owned by insiders.

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.